Latest News
Organon acquires US rights to TOFIDENCE from Biogen
1 April 2025 - Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company Biogen Inc (Nasdaq:BIIB).TOFIDENCE, launched in M...
Oncopeptides secures FDA approval to resume OPD5 clinical development
1 April 2025 - Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, announced on Tuesday that the US Food and Drug Administration (FDA) has lifted the clinical hold on OPD5, its next-generation Peptide Drug Con...
Bonesupport submits FDA application for CERAMENT V
1 April 2025 - Swedish orthobiologics company Bonesupport Holding AB (STO:BONEX) said on Tuesday that it has submitted a market authorisation application to the US Food and Drug Administration (FDA) for CERAMENT V (vancomycin), its antibiotic-eluting...
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
1 April 2025 - Clinical-stage biopharmaceutical company Spinogenix Inc announced on Monday that it has commenced enrolment for a Phase 2 trial of SPG302 intended for the treatment of people with schizophrenia.This follows approval of the company'...
GenomOncology collaborates with Chronetyx Laboratories for comprehensive genomic profiling in cancer care
1 April 2025 - Precision medicine software company GenomOncology on Monday announced a collaboration with Chronetyx Laboratories, a provider of advanced diagnostic solutions, to accelerate cancer care through comprehensive genomic profiling.The partn...